Two Sigma Advisers
RUBY

Two Sigma Advisers’s Rubius Therapeutics, Inc RUBY Stock Holding History

Two Sigma Advisers’s Portfolio RUBY Stock Details RUBY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-29,400
Closed -$13K – 2764
2022
Q3 		$13K Sell
29,400
-534,000
-95% -$400K ﹤0.01% 2471
2022
Q2 		$479K Buy
563,400
+308,600
+121% +$518K ﹤0.01% 1946
2022
Q1 		$1.4M Buy
254,800
+41,000
+19% +$260K ﹤0.01% 1452
2021
Q4 		$2.07M Buy
213,800
+70,500
+49% +$978K 0.01% 1184
2021
Q3 		$2.56M Buy
143,300
+111,100
+345% +$2.42M 0.01% 1117
2021
Q2 		$786K Buy
32,200
+20,200
+168% +$505K ﹤0.01% 1744
2021
Q1 		$318K Sell
12,000
-13,000
-52% -$190K ﹤0.01% 2198
2020
Q4 		$190K Sell
25,000
-1,200
-5% -$7.13K ﹤0.01% 2187
2020
Q3 		$131K Sell
26,200
-4,200
-14% -$22.2K ﹤0.01% 2241
2020
Q2 		$182K Buy
30,400
+2,500
+9% +$14.8K ﹤0.01% 2270
2020
Q1 		$124K Buy
+27,900
New +$207K ﹤0.01% 2273

Other funds holding RUBY

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return
SOMRS
State of Michigan Retirement System Lansing, Michigan $18.9B AUM 27.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Advisers's RUBY Position: Q4 2022 in Review

Two Sigma Advisers sold out of Rubius Therapeutics, Inc (RUBY) in Q4 2022, closing a stake of 29,400 shares — an estimated $13K sold.

Two Sigma Advisers first reported a position in RUBY in Q1 2020 and held it in 11 quarters. The position peaked at $2.56M in Q3 2021. 42 funds tracked by Wall St. Rank hold RUBY as of Q4 2022.

  • Two Sigma Advisers reported no remaining Rubius Therapeutics, Inc position as of Q4 2022 after selling out during the quarter.
  • Two Sigma Advisers sold 29,400 Rubius Therapeutics, Inc shares in Q4 2022, an estimated $13K.
  • Two Sigma Advisers first reported a position in Rubius Therapeutics, Inc in Q1 2020 and held it in 11 quarters.
  • Two Sigma Advisers's Rubius Therapeutics, Inc position peaked at $2.56M in Q3 2021.
  • 42 funds tracked by Wall St. Rank held Rubius Therapeutics, Inc as of Q4 2022.

Based on Two Sigma Advisers's 13F filing for Q4 2022, filed 14 Feb 2023.